Related Experiment Videos
Aniracetam reverses memory impairment in rats
J R Martin1, J L Moreau, F Jenck
1F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Pharmacological Research
|February 1, 1995
Summary
Aniracetam, a nootropic drug, effectively reversed memory loss caused by scopolamine in rats. This memory enhancement was consistent across multiple tests, showing aniracetam
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Scopolamine administration induces amnesia by reducing cholinergic function.
- Aniracetam is a pyrrolidinone derivative investigated for cognitive-enhancing properties.
Purpose of the Study:
- To evaluate the efficacy of aniracetam in ameliorating scopolamine-induced amnesia in a rat model.
- To determine the dose-response relationship of aniracetam for reversing amnesia.
Main Methods:
- Aniracetam was administered orally to female rats immediately after inhibitory avoidance response acquisition.
- Scopolamine was used to induce amnesia, with vehicle-treated groups serving as controls.
- A dose-response study identified the minimum effective oral dose of aniracetam.
Main Results:
- The lowest effective oral dose of aniracetam was found to be 50 mg/kg.
- Aniracetam (50 mg/kg) significantly improved passive avoidance responding in amnesic rats (53% correct vs. 9% for vehicle).
- Results remained consistent over a 1-year testing period, demonstrating replicability.
Conclusions:
- Aniracetam reliably enhances memory in an animal model of reduced cholinergic function.
- The findings support aniracetam's potential as a therapeutic agent for memory impairments.